Trend of Multidrug and Extensively Drug Resistant Tuberculosis in a Tuberculosis Referral Hospital, 2001~2005.
10.4046/trd.2008.64.3.187
- Author:
Doosoo JEON
1
;
Dongok SHIN
;
Hyungseok KANG
;
Nackmoon SUNG
;
Kyungsoon KWEON
;
Eun SHIN
;
Kyungsoon KIM
;
Myunghee LEE
;
Seungkyu PARK
Author Information
1. National Masan Tuberculosis Hospital, Masan, Korea. sooli10kr@yahoo.co.kr
- Publication Type:Original Article
- Keywords:
Tuberculosis;
Multidrug resistance;
Extensively drug-resistant tuberculosis
- MeSH:
Drug Resistance;
Drug Resistance, Multiple;
Extensively Drug-Resistant Tuberculosis;
Hospitals, Chronic Disease;
Humans;
Medical Records;
Nitroimidazoles;
Private Sector;
Referral and Consultation;
Retrospective Studies;
Sulfonamides;
Tuberculosis;
Tuberculosis, Multidrug-Resistant;
Tuberculosis, Pulmonary
- From:Tuberculosis and Respiratory Diseases
2008;64(3):187-193
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) are serious threats to worldwide tuberculosis control, but the national burden and the trends of infectious spread are largely unknown. METHODS: We retrospectively reviewed the results of drug sensitivity tests and medical records of patients that were diagnosed with culture-confirmed pulmonary tuberculosis and were admitted to the National Masan Tuberculosis Hospital between 2001 and 2005. RESULTS: From 2001 to 2005, the proportion of MDR-TB among new cases was 9.2%, 13.8%, 16.9%, 23% and 27.0% in 2001, 2002, 2003, 2004 and 2005, respectively, and the proportion of MDR-TB among previously treated cases was 58.5%, 60.2%, 62.7%, 61.7% and 71.3% in 2001, 2002, 2003, 2004 and 2005, respectively. A significant increasing trend could be discerned for MDR-TB among both new and previously treated cases (p<0.001, p=0.002 for trend, respectively). The proportion of XDR-TB among new cases was 0%, 2.3%, 3.1%, 2.5% and 6.3% in 2001, 2002, 2003, 2004 and 2005, respectively, and the proportion of XDR-TB among previously treated cases was 9.1%, 15.7%, 17.3%, 19.9% and 19.1% in 2001, 2002, 2003, 2004 and 2005, respectively. A significant increasing trend could be discerned for XDR-TB among both new and previously treated cases (p=0.005, p<0.001 for trend, respectively). CONCLUSION: Both MDR-B and XDR-TB were gradually increased among both new and previously treated cases. Integrated national surveillance, including the public and private sectors, will be needed to estimate the exact status of antituberculous drug resistance.
